Palisade Bio, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Carlsbad, CA
PALI chart
What traders are saying about $PALI
Latest postsPalisade Bio, Inc. news
- Live Palisade Bio, Inc. (PALI) Technical Analysis
Traders Union ·
- Palisade Bio, Inc. (PALI) Earnings Date, Reports and Estimates
Traders Union ·
- Palisade Bio doses first patient in ulcerative colitis trial By Investing.com
Investing.com Nigeria ·
- Palisade Bio doses first patient in Phase 2b tr...
Pluang ·
- Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
Yahoo Finance ·
- Palisade Bio, Inc. (PALI) Stock Price Prediction for 2026, 2030-2040
Traders Union ·
- Palisade Bio, Inc. Estimates – NASDAQ:PALI
TradingView ·
- Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
Yahoo Finance ·
- Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
Yahoo Finance ·
- Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Yahoo Finance ·
- Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
marketbeat.com ·
- Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Yahoo Finance ·
Palisade Bio, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | $0 | $250,000 | $0 |
| Net income | -$16.8M | -$14.4M | -$12.3M | -$14.3M |
| Diluted EPS | $-0.30 | $-10.19 | $-27.01 | $-16.53 |
| Total assets (year end) | $134.3M | $10.9M | $14.1M | $15.8M |
| Cash and equivalents (year end) | $133.4M | $9.8M | $12.4M | $12.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Palisade Bio, Inc.
- Ticker
- PALI (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Carlsbad, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1357459
- Former names
- PALISADE BIO, INC., Seneca Biopharma, Inc., Neuralstem, Inc.
Frequently asked questions
What exchange is Palisade Bio, Inc. listed on?
Palisade Bio, Inc. trades on the Nasdaq under the ticker symbol PALI.
What industry is Palisade Bio, Inc. in?
Palisade Bio, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Palisade Bio, Inc. headquartered?
Palisade Bio, Inc.'s business address on file with the SEC is in Carlsbad, CA.
When does Palisade Bio, Inc.'s fiscal year end?
Palisade Bio, Inc.'s fiscal year ends on December 31.
How much revenue did Palisade Bio, Inc. report?
Palisade Bio, Inc. reported $0 in revenue for calendar year 2024, according to its SEC filings.